The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles
- PMID: 17554513
- DOI: 10.1007/978-3-540-68976-8_12
The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles
Abstract
Recent evidence suggests that mesenchymal stem cells (MSC) selectively proliferate to tumors and contribute to the formation of tumor-associated stroma. The biological rationale for tumor recruitment of MSC remains unclear but may represent an effort of the host to blunt tumor cell growth and improve survival. There is mounting experimental evidence that normal stromal cells can revert malignant cell behavior, and separate studies have demonstrated that stromal cells can enhance tumor progression after acquisition of tumor-like genetic lesions. Together, these observations support the rationale for modifying normal MSC to deliver therapeutic proteins directly into the tumor microenvironment. Modified MSC can produce high concentrations of antitumor proteins directly within the Tumor mass, which have been shown to blunt tumor growth kinetics in experimental animal model systems. In this chapter we will address the biological properties of MSC within the tumor microenvironment and discuss the potential use of MSC and other bone marrow-derived cell populations as delivery vehicles for antitumor proteins.
Similar articles
-
Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents.J Natl Cancer Inst. 2004 Nov 3;96(21):1593-603. doi: 10.1093/jnci/djh299. J Natl Cancer Inst. 2004. PMID: 15523088
-
Mesenchymal stem cells: flip side of the coin.Cancer Res. 2009 Feb 15;69(4):1255-8. doi: 10.1158/0008-5472.CAN-08-3562. Epub 2009 Feb 10. Cancer Res. 2009. PMID: 19208837 Review.
-
Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.Cancer Res. 2008 Dec 1;68(23):9614-23. doi: 10.1158/0008-5472.CAN-08-0451. Cancer Res. 2008. PMID: 19047138
-
Therapeutic potential of genetically modified mesenchymal stem cells.Gene Ther. 2008 May;15(10):711-5. doi: 10.1038/gt.2008.35. Epub 2008 Mar 20. Gene Ther. 2008. PMID: 18356815 Review.
-
Bone marrow-derived mesenchymal stem cells and the tumor microenvironment.Cancer Metastasis Rev. 2010 Jun;29(2):249-61. doi: 10.1007/s10555-010-9222-7. Cancer Metastasis Rev. 2010. PMID: 20411303 Review.
Cited by
-
Heparin-binding epidermal growth factor-like growth factor and mesenchymal stem cells act synergistically to prevent experimental necrotizing enterocolitis.J Am Coll Surg. 2012 Oct;215(4):534-45. doi: 10.1016/j.jamcollsurg.2012.05.037. Epub 2012 Jul 21. J Am Coll Surg. 2012. PMID: 22819639 Free PMC article.
-
Ovarian cancer-derived lysophosphatidic acid stimulates secretion of VEGF and stromal cell-derived factor-1 alpha from human mesenchymal stem cells.Exp Mol Med. 2010 Apr 30;42(4):280-93. doi: 10.3858/emm.2010.42.4.027. Exp Mol Med. 2010. PMID: 20177148 Free PMC article.
-
The tumor microenvironment in colorectal carcinogenesis.Cancer Microenviron. 2010 Mar 5;3(1):149-66. doi: 10.1007/s12307-010-0038-3. Cancer Microenviron. 2010. PMID: 21209781 Free PMC article.
-
Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk.Mol Cancer. 2010 Nov 18;9:295. doi: 10.1186/1476-4598-9-295. Mol Cancer. 2010. PMID: 21087507 Free PMC article.
-
Cytotherapy with naive rat umbilical cord matrix stem cells significantly attenuates growth of murine pancreatic cancer cells and increases survival in syngeneic mice.Cytotherapy. 2010 May;12(3):408-17. doi: 10.3109/14653240903548194. Cytotherapy. 2010. PMID: 20345214 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical